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Characterization of an A-kinase 
anchoring protein-like suggests an alternative 
way of PKA anchoring in Plasmodium falciparum
Kossiwa Bandje1,2,3, Bernina Naissant2,3,4,5, Pascal Bigey2,6, Murielle Lohezic1,2,3, Marlène Vayssières2,7, 
Magali Blaud2,7, Laetitia Kermasson1,2,3, José‑Juan Lopez‑Rubio8, Gordon Langsley2,4,5,9, 
Catherine Lavazec2,3,4,5,10, Philippe Deloron1,2,3 and Anaïs Merckx1,2,3*
Abstract 
Background: The asexual intra‑erythrocytic multiplication of the malaria parasite Plasmodium falciparum is regulated 
by various molecular mechanisms. In eukaryotic cells, protein kinases are known to play key roles in cell cycle regula‑
tion and signaling pathways. The activity of cAMP‑dependent protein kinase (PKA) depends on A‑kinase anchoring 
proteins (AKAPs) through protein interactions. While several components of the cAMP dependent pathway—includ‑
ing the PKA catalytic and regulatory subunits—have been characterized in P. falciparum, whether AKAPs are involved 
in this pathway remains unclear. Here, PfAKAL, an open reading frame of a potential AKAP‑like protein in the P. falcipa-
rum genome was identified, and its protein partners and putative cellular functions characterized.
Methods: The expression of PfAKAL throughout the erythrocytic cycle of the 3D7 strain was assessed by RT‑qPCR 
and the presence of the corresponding protein by immunofluorescence assays. In order to study physical interactions 
between PfAKAL and other proteins, pull down experiments were performed using a recombinant PfAKAL protein 
and parasite protein extracts, or with recombinant proteins. These interactions were also tested by combining bio‑
chemical and proteomic approaches. As phosphorylation could be involved in the regulation of protein complexes, 
both PfAKAL and Pf14‑3‑3I phosphorylation was studied using a radiolabel kinase activity assay. Finally, to identify 
a potential function of the protein, PfAKAL sequence was aligned and structurally modeled, revealing a conserved 
nucleotide‑binding pocket; confirmed by qualitative nucleotide binding experiments.
Results: PfAKAL is the first AKAP‑like protein in P. falciparum to be identified, and shares 23 % sequence identity with 
the central domain of human AKAP18δ. PfAKAL is expressed in mature asexual stages, merozoites and gametocytes. 
In spite of homology to AKAP18, biochemical and immunochemical analyses demonstrated that PfAKAL does not 
interact directly with the P. falciparum PKA regulatory subunit (PfPKA‑R), but instead binds and colocalizes with Pf14‑
3‑3I, which in turn interacts with PfPKA‑R. In vivo, these different interactions could be regulated by phosphorylation, 
as PfPKA‑R and Pf14‑3‑3I, but not PfAKAL, are phosphorylated in vitro by PKA. Interestingly, PfAKAL binds nucleotides 
such as AMP and cAMP, suggesting that this protein may be involved in the AMP‑activated protein kinase (AMPK) 
pathway, or associated with phosphodiesterase activities.
Conclusion: PfAKAL is an atypical AKAP that shares common features with human AKAP18, such as nucleotides 
binding. The interaction of PfAKAL with PfPKA‑R could be indirectly mediated through a join interaction with Pf14‑
3‑3I. Therefore, PfPKA localization could not depend on PfAKAL, but rather involves other partners.
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Background
Malaria kills about 438,000 people per year, mostly in 
Africa [1]. Plasmodium falciparum, a protozoan parasite, 
is the deadliest of the five known species responsible for 
the disease in humans. Current malaria control strategies 
rely primarily on insecticide-treated bed nets and drugs. 
However, the extensive spread of drug resistance limits 
the armamentarium [2]. The identification and character-
ization of novel Plasmodium-specific proteins and their 
joint interaction may lead to the development of new 
therapeutic strategies.
Protein phosphorylation is one of the most common 
post-translational modifications involved in cellular 
communication. The phosphorylation status of a pro-
tein is determined by the balance between the activi-
ties of kinases and phosphatases. The cAMP-signalling 
pathway plays a central role in many developmental 
processes in eukaryotes, by activating molecules such 
as the cAMP-dependent protein kinase (PKA). A high 
concentration of cAMP interacting with regulatory 
subunits liberates catalytic subunits of PKA (PKA-C) 
to phosphorylate its target proteins. In eukaryotes, the 
subcellular specificity of PKA largely depends on its 
interaction with A-kinase anchoring proteins (AKAPs). 
This interaction ensures the spatio-temporal control of 
PKA activity, by tethering the enzyme close to its sub-
strates, and by interacting with phosphatases and phos-
phodiesterases (PDE) [3–5].
AKAP proteins have a wide range of localizations, and 
can be associated with membranes, cellular organelles, 
and compartments. In the nucleus for instance, their 
localization is controlled through protein-lipid or pro-
tein–protein interactions [6]. The subcellular localization 
of AKAPs can be dynamic and regulated by phospho-
rylation [3]. Human AKAP18 is a low molecular weight 
AKAP with four different isoforms with distinct target-
ing domains. Because of their localizations, AKAP18 
isoforms are involved in different cellular mechanisms. 
AKAP18δ, the larger isoform, has been reported to 
anchor PKA for both phosphorylation of aquaporin-2 
in kidneys [4] and phosphorylation of phospholamban 
in the heart [5]. AKAP18δ also binds PDE4A isoforms 
within its central region [6]. A common central domain 
of AKAP18δ/γ has been described, whose structure 
resembles the 2H phosphoesterase family, harbouring a 
pair of conserved His-x-Thr motifs [7].
In P. falciparum, several effectors of the cAMP-path-
ways including cAMP-dependent protein kinase cata-
lytic subunit (PKA-C) and regulatory subunit (PKA-R) 
homologues [8, 9], nucleotide cyclases [10] and phos-
phodiesterase [11, 12] have been identified. Importantly, 
the PfPKA-C knock-out is lethal and the PfPKA-R over-
expression inhibits the growth of the parasite suggesting 
a crucial role of these effectors in the development and 
survival of the parasite [9].
In this study, the expression and function of the P. fal-
ciparum protein encoded by PF3D7_0512900/PFE0640w 
[PlasmoDB.org], herein named PfAKAL (P. falciparum 
A Kinase anchoring protein-like), based on its amino 
acid sequence homology with human AKAP18 [7], were 
investigated. However, unlike human AKAP18, PfPKA 
targeting and localization do not depend on direct bind-
ing to PfAKAL. This suggests that the subcellular locali-
zation of PfPKA may result from an alternative process 
and that the function of PfAKAL may differ from its 
human orthologs.
Methods
RNA extraction and real‑time quantitative PCR 
experiments
Plasmodium falciparum 3D7 strain cultures were syn-
chronized twice with 5  % d-sorbitol solution. The 
infected red blood cells were harvested every 8  h in 
order to have all the different intra-erythrocytic stages. 
Rings, early and late trophozoites, and schizont stages 
were harvested and conserved in Trizol. Stage-spe-
cific mRNA were extracted, and cDNA synthesized by 
RT-PCR. CGTAACGATGTTTTATAT (forward) and 
TAATATTTCTTTTGCGGG (reverse) primers spe-
cific to 140  pb of the pfakal gene were designed. Real-
time Quantitative PCR was performed on the cDNA to 
estimate pfakal expression levels throughout the intra-
erythrocytic development, using SensiFastSYBR NO-
ROX Mix 2× (Bioline) and Rotor-gene™ 600 (Corbett 
Research), and 0.208  μM of each primer. The following 
PCR cycling conditions were used: initial heat activation 
step at 95 °C for 1 min, followed by 35 cycles of 95 °C for 
15 s, 60 °C for 1 min and 72 °C for 5 min. All PCR reac-
tions including negative controls (water) were carried 
out in duplicate, and a minimum of three experiments 
was carried out for each sample. The p90 gene, encod-
ing seryl-tRNA synthetase involved in DNA duplication 
was used as reference gene, and to characterize the RNA 
samples prior to the pfakal expression analysis. AAG-
TAGCAGGTCATCGTGGTT (forward) and TTCG-
GCACATTCTTCCATAA (reverse) primers specific to 
158  pb of the p90 gene were designed. The amplifica-
tion specificity for each primer pair was determined by 
melting-curve analysis of each PCR product. The pfakal 
transcript abundance was calculated using the 2−ΔΔCt 
method where Ct is the threshold cycle, and Ct=(
Ct pfakal−Ct p90
)
stage x
−
(
Ct pfakal−Ct p90
)
reference stage
.
The result for each sample was expressed by calculat-
ing the mean and standard deviations between the three 
experiments. A statistical analysis was performed with a 
Kruskal–Wallis test.
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Molecular cloning and bacterial expression of recombinant 
proteins
Oligonucleotides were designed for amplification of a 
798  bp region on chromosome 5, carrying the pfakal 
coding sequence and cloning into pGEX-6P1 (forward 
primer/BamH1, cgGGATCCATGAATATTAAAAGAAG 
CATATACCA; reverse primer/Xho1, cgCTCGAGTC 
AAAGATTAAACTCAGACACG) and pRSF Duet (for-
ward primer/BamH1, GGATCCAATGAATATTAAAAG 
AAGCATATACCATTATTTAAG; reverse primer/Not1: 
GCGGCCGCTCAAAGATTAAACTCAGACACGATT 
T). Pf14-3-3I [PlasmoDB: MAL8P1.69/PF3D7_0818200] 
and PfPKA-R [PlasmoDB: PFL1110c/PF3D7_1223100] 
genes were also amplified by PCR prior cloning into pRS-
FDuet vector (forward pf14-3-3I primer/EcoRI: GAATCC 
GATGGCAACATCTGAAGAATT; reverse pf14-3-3I 
primer/Not1 GCGGCCGCTCATTCTAATCCTTCGTC; 
forward pfpka-r primer/EcoRI GAATTCGATGGGCA 
ATGTGTGCAC; reverse pfpka-r primer/Not1 GCGGCC 
GCTTAATTTTCATCAATACAAGTTGTATCCA). 
After amplification from a P. falciparum cDNA library, 
the PCR products were digested prior insertion in the 
plasmids. For the different cloning steps, the inserts were 
verified by sequencing, and the plasmids were sepa-
rately transformed into Escherichia coli BL21 Codon Plus 
(Stratagene) cells.
GST-PfAKAL, (His)6-PfPKA-R and (His)6-Pf14-3-3I 
protein expressions were induced for 4 and 6 h with 0.3 
and 0.5  mM of Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) at 37  °C, respectively. (His)6-PfAKAL expression 
was induced overnight with 0.3  mM of IPTG at 20  °C. 
All purification steps were performed at 4  °C. The bac-
terial pellets were lysed with lysosyme and by sonication 
in lysis buffer with ComplexTM mixture protease inhibi-
tor tablet from Roche Applied Science. (GST-PfAKAL 
lysis buffer: 1× PBS, pH 7.5, 0.1 % Triton, 1 mM EDTA; 
(His)6-PfAKAL, (His)6-PF14-3-3I and (His)6-PfPKA-R 
lysis buffer: 20 mM Tris–HCl pH 8, 300 mM NaCl, 1 % 
Triton ×100). The lysates were cleared by centrifugation 
(9000 rpm at 4  °C for 1 h), and the soluble fraction was 
incubated for 1.5 h using mild agitation with glutathione-
agarose (Sigma-Aldrich) or Ni–NTA-agarose (Invitro-
gen) resin.
GST-PfAKAL slurry was washed in lysis buffer, and the 
fusion protein eluted with elution buffer (30 mM Tris, pH 
8.0, 15 mM NaCl, 20 mM glutathione). (His)6 tagged pro-
tein slurry was washed three times in lysis buffer, twice 
in lysis buffer with 20  mM imidazole, and eluted with 
elution buffer (lysis buffer with 250 mM Imidazole). All 
recombinant protein preparations were confirmed by 
anti-GST or anti-(His)6 western blot analysis.
Gel filtration analysis
To determine if proteins are forming dimer, gel filtration 
analysis were performed on the eluted fractions obtained 
after affinity purification of (His)6-Pf14-3-3I and (His)6-
PfPKA-R. Samples were loaded onto a Superdex S200 
10/300 Increase column (GE Healthcare) and gel filtra-
tion were carried out using GF buffer (20 mM Tris–HCl 
at pH 8, 300 mM NaCl). The fractions corresponding to 
the pic detected by UV were analysed by a 12.5 % SDS-
PAGE to confirm the size of the eluted proteins.
Immunofluorescence assay (IFA)
In vivo immunizations were carried out on 6-week old 
Swiss female mice (Janvier, Le Genest De L’Isle, France). 
Four mice were first immunized by an intraperitoneal 
injection of 10  µg of recombinant PfAKAL fused to a 
GST tag (produced as described above) homogenized 
in 1 mg aluminium hydroxide (Alugel, Serva) in a 100 µl 
saline volume. Two boosts of 10  µg of recombinant 
PfAKAL fused to a (His)6-tag homogenized in 1 mg alu-
minium hydroxide in a 100 µl saline volume were admin-
istered on days 21 and 42. Blood samples were collected 
by retro-orbital bleeding at day 56. Rat Anti Pf14-3-3I 
antibodies were obtained according to [13].
Plasmodium falciparum 3D7 strain infected red blood 
cells with 7  % parasitaemia (mostly trophozoites and 
schizonts) were washed in PBS. The cells were fixed with 
methanol. After overnight incubation in PBS, 2  % BSA 
the blood smears were incubated with one of the fol-
lowing antisera: anti-PfAKAL mouse antiserum diluted 
1:500 and anti-Pf14-3-3I rat antibodies diluted 1:100, or 
an anti-PfAMA1/28G2d described in [14] and diluted 
1/1.000 (kindly provided by J.C. Barale, Institut Pasteur, 
Paris). After washes, the slides were incubated with Alex-
aFluor conjugated secondary antibodies against mouse 
or rat IgG containing 1/20,000 Hoechst (Hoechst 33,342, 
trihydrochloride, trihydrate 10  mg⁄mL) and mounted in 
vectashield (Vectorslab). Samples were observed at 100× 
magnification using an Olympus fluorescent microscope. 
Thereafter, the PfAKAL and Pf14-3-3I cellular localiza-
tions were analysed using the Imaris deconvolution soft-
ware from Bitplane.
Peptide array experiment
128 overlapping 15 mer-peptides with a two amino 
acids frameshift, derived from the full-length PfAKAL 
amino acid sequence were synthesized on nitrocellu-
lose membrane. The membrane was incubated in a 1 µM 
(His)6-PfPKA-R protein recombinant solution. An anti-
polyhistidine western blot was performed to identify the 
peptides having interacted with (His)6-PfPKA-R.
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Pull‑down experiments with parasite protein extracts
Plasmodium falciparum (3D7) pellets were sonicated in 
RIPA buffer (30 mM Tris, pH 8.0, 150 mM NaCl, 20 mM 
MgCl2, 1  mM EDTA, 1  mM dithiothreitol, 10  µM ATP, 
0.5 % Triton X-100, 1 % Nonidet P-40, Complete EDTA 
free protease inhibitors Coktail (Roche), and PhosSTOP 
Phosphatase inhibitors Coktail (Roche). The lysates were 
cleared by centrifugation (15,000 rpm for 30 min at 4 °C), 
and the total amount of protein in the supernatant was 
measured using a Coomassie Plus Protein Assay Rea-
gent (Pierce). The beads coated with GST, GST-PfAKAL 
or AMP were incubated with the parasite extracts or in 
RIPA buffer alone at 4 °C, under mild agitation for 90 min 
(100  µg of total parasite proteins for 10  µg of recombi-
nant protein on beads). The beads were then washed 
three times in RIPA buffer, and once in RIPA buffer with 
0.1 % SDS. The precipitated complexes were analysed by 
mass spectrometry (Proteomic Facility, 3P5 Université 
Paris Descartes).
Protein/protein and protein/nucleotide interaction 
experiments
GST, GST-PfAKAL glutathione beads were incubated 
with (His)6-Pf14-3-3I or (His)6-PfPKA-R recombinant 
proteins. Also, GST and GST-PfPKA-R glutathione beads 
were incubated in (His)6-Pf14-3-3I recombinant protein. 
Adenosine monophosphate (AMP) or cyclic AMP cross-
linked agarose beads were incubated in recombinant 
(His)6-PfAKAL protein solution for 2 h at 4 °C.
For all pull down experiments, beads were washed in 
RIPA buffer, and the protein complexes were analysed 
by SDS-PAGE and an anti-histidine western blot (Sigma 
Aldrich Monoclonal Anti-polyHistidine Peroxidase Con-
jugate) was performed to identify interactions.
Kinase assay
Assays were performed in a standard reaction (30  µl) 
containing 50  mM MOPS pH7, 0.5  mM MgCl2, 15  µM 
ATP, 5 µCi of [γ-32P]ATP (3000 Ci/mmol; Perkin Elmer) 
and 1 µM of recombinant (His)6-PfPKA-R, 1 µM recom-
binant (His)6-Pf14-3-3I or 1  µM recombinant (His)6-
PfAKAL. The reactions were initiated by addition of 
1  µM commercial bovine PKAc (Sigma Aldrich P2645), 
with or without 1 µM H89, a potent PKA inhibitor. The 
kinase reactions, proceeded for 30  min at 30  °C, were 
stopped by the addition of Laemmli buffer, boiled for 
3 min and analysed by electrophoresis on 8 % SDS–poly-
acrylamide gel. The gels were dried and submitted to 
autoradiography.
PfAKAL structural model and binding site predictions
Sequence alignments of PfAKAL to Plasmodium yoe-
lii AKAP18 [PlasmoDB: PY04627], a Plasmodium vivax 
ortholog [PlasmoDB: PVX080595] and human AKAP18 
γ isoform were performed using ClustalO, and visualized 
using BOXSHADE. Amino acid sequences of PfAKAL 
was submitted to the I-TASSER server for structural pre-
diction [15, 16]. Protein structures were visualized using 
PyMol version 0.99rc6.
Results and discussion
In silico identification of a P. falciparum ORF related to an 
AKAP
BLASTP searches of the PlasmoDB database were per-
formed, using as queries a variety of AKAP sequences 
from different organisms, identifying a single P. falci-
parum polypeptide displaying significant amino acid 
homology. The predicted 265-residue protein, PfAKAL 
[PlasmoDB PFE0640w/PF3D7_0512900] displays 23  % 
identity, and 33  % similarity to human AKAP18γ. The 
parasite protein also shows homology to predicted pro-
teins from other Plasmodium species, such as 50 and 
44 % identities with P. yoelii [PlasmoDB: PY04627], and 
P. vivax [PlasmoDB: PVX080595], respectively (Fig.  1). 
However, PfAKAL does not share all of the characteris-
tics typical of mammalian AKAPs, such as, for example, 
a transmembrane domain, N-myristoylation, or palmy-
toylation sites suggesting that PfAKAL is cytosolic as are 
human AKAP18δ and AKAP18γ [17]. In addition to its 
homology with the core domain of human AKAP18γ, 
PfAKAL contains a Pfam AKAP7 2′5′ RNA ligase-like 
domain (pfam10469). This domain corresponds to the 
N-terminal part of AKAP7 which is known to play a 
role in regulating PKA-mediated gene transcription in 
somatic cells and oocytes [17]. PfAKAL also harbours 
two His-x-Thr/Ser motifs (Fig.  1) that define the 2H 
phosphoesterase family, including RNA ligases and cyclic 
nucleotide phosphoesterases [18]. Such residues are con-
served in the AKAP18δ/γ from different organisms [7]. 
Despite the weak amino acid homology, PfAKAL is the 
only AKAP-like protein to be identified in the predicted 
proteome of P. falciparum and its role remains unknown.
PfAKAL expression and localization throughout the 
erythrocytic stage
To determine whether pfakal is expressed during red 
blood cell infection, real-time quantitative PCR (RT-
qPCR) experiments were performed on total cDNA 
from synchronized parasite erythrocytic stages from 
in vitro cultures of the 3D7 strain [19]. Primers efficiency 
were validated at 1.98 and 1.93 for p90 and pfakal gene 
respectively, and a Kruskal–Wallis test was performed on 
the results, with a p value =  0.0077. The pfakal gene is 
expressed throughout the erythrocytic cycle, with maxi-
mal expression in mature trophozoite stages (Fig. 2), thus 
the expression levels were normalized to pfakal gene 
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transcription level in late trophozoites (reference stage in 
ΔΔCt equation). The results correspond with those previ-
ously described in a large scale study [20].
To analyse the subcellular distribution and stage speci-
ficity of PfAKAL expression, immunofluorescence assays 
were carried out on P. falciparum-infected erythrocytes 
harbouring parasites at different development stages 
(Fig.  3). In asexual parasites PfAKAL was undetectable 
in ring stages (Fig.  3a), with expression predominantly 
in late trophozoites and schizonts. Interestingly, a dif-
fuse subcellular localization of PfAKAL was observed 
in the parasite cytoplasm and in the nucleus in tropho-
zoite stages, whereas it was mostly nuclear in schizonts 
(Fig.  3b, c). In sexual stages, PfAKAL was also detected 
in the cytoplasm of the parasite, although it mainly accu-
mulates around the nucleus (Fig.  3d–g). To analyse the 
PfAKAL localization on merozoïtes immunofluorescence 
assays were also performed with a dual labelling using 
mouse anti-PfAKAL antibody with a rat anti-PfAMA1, 
a control labelling parasite plasma membrane. PfAKAL 
shares partial location with PfAMA1, and the IFA results 
showed that PfAKAL is expressed in egressing (Fig.  4a) 
and invading (Fig.  4b) merozoites, in agreement with a 
wide proteomic analysis of P. falciparum cycle [21].
These results strongly suggest that PfAKAL is expressed 
at the transcript level as well at the protein level during 
the intra-erythrocytic development of P. falciparum par-
asites, but PfAKAL remains within the parasite and is not 
exported to the infected red blood cell cytosol. The data 
is consistent with the in silico analysis suggesting that 
PfAKAL is not a membrane associated protein.
PfPKA anchoring does not depend on direct interaction 
with PfAKAL
In human cells, AKAPs bind PKA through an amphip-
athic α-helical structure consisting of 14–18 amino acids 
(RII-binding domain), which interacts with the hydro-
phobic groove formed by the N-terminal dimerization 
and docking (D/D) domain of PKA-R subunits [22]. To 
investigate the potential interaction between PfAKAL 
and PfPKA regulatory subunit, recombinant proteins 
were produced and used for GST pull-down assays. 
Fig. 1 Alignments of PfAKAL, P. yoelii AKAP18 (PyAKAP18g) and P. vivax ortholog (PVX080595) with Human AKAP18γ. In this box shade representa‑
tion of the alignment, identical and similar residues are shaded respectively in black and grey. The residues involved in nucleotide binding are 
labeled with triangles above the alignment, the conserved residues interacting with the adenosine (red) and the residues interacting with the phos‑
phate (black) moieties of 5′AMP in the human AKAP18 complex crystal structure. The human AKAP18 core domain is underlined with plain line
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Purified GST-PfPKA-R beads were incubated in puri-
fied (His)6-PfAKAL solution. Anti-polyhistidine western 
blot analysis failed to reveal any interaction between the 
two proteins, suggesting that there is no direct interac-
tion between the two proteins (Fig.  5a, b, lane 8). The 
ability of PfAKAL to bind PfPKA-R was also investigated 
using a peptide array analysis. To this end, recombinant 
(His)6-PfPKA-R was incubated with a membrane con-
taining PfAKAL derived peptides and again, anti-polyhis-
tidine immunoblot analysis did not reveal the presence of 
(His)6-PfPKA-R on the membrane. Thus, this particular 
array did not reveal any interaction between the two pro-
teins. The two positive dots correspond to a positive con-
trol peptide (containing six histidines, bottom line) and a 
derived peptide from PfAKAL containing three histidines 
(top line) (Fig. 5c).
Even though peptide array technology has been used 
successfully to study PKA-R/AKAP interaction in other 
organisms [23, 24], the fact that a 15-mer peptide doesn’t 
mimic the complete docking site cannot be excluded, 
nor the possibility of peptide and PfAKAL or PfPKA-R 
recombinant protein mis-folding.
Therefore, to determine if PfPKA might be an inter-
acting partner of PfAKAL in the parasite, pull-down 
experiments using recombinant GST-PfAKAL and native 
parasite protein extracts were performed and followed by 
mass spectrometry nLC-MSMS analysis. This approach 
confirmed the absence of any direct interaction between 
PfAKAL and PfPKA-R.
Furthermore, an In silico analysis of PfPKA-R high-
lighted a difference of the N-terminal portion compared 
to the equivalent N-terminal part of human PKA-R, as 
it does not share the prototypical helical bundle that 
allows dimerization of PKA-R subunits, and the dock-
ing of AKAP proteins [25]. An analytical gel filtration 
analysis on (His)6-PfPKA-R was also performed, and 
showed only one pic (Fig. 5d). This pic corresponds to a 
monomer of (His)6-PfPKA-R, according to the calibra-
tion of the Superdex S200 10/300 Increase column (GE 
Healthcare) around a molecular weight of 50 kDa. The 
eluted fractions from the pic were collected and ana-
lysed by 12.5 % SDS-PAGE to confirm that the pic cor-
responds to (His)6-PfPKA-R. These observations are in 
agreement with the lack of direct interaction between 
PfAKAL and PfPKA-R, and raise the hypothesis of an 
alternative way of PKA anchoring in the malaria par-
asite. This hypothesis was recently reinforced by the 
antimalarial activity of a human AKAP disruptor pep-
tide STAD-2, through a PKA-independent mechanism 
[26], and by a recent analysis highlighting the fact that 
AKAP can only be found in animal genomes, and likely 
evolved in conjunction with multicellularity [27]. Sev-
eral PKA phosphorylation sites have however been 
identified in the N-terminal part of PfPKA-R [28–30], 
and Haste and colleagues suggested that these sites 
might be involved in the docking of other proteins such 
as Pf14-3-3 [25].
PfAKAL/PfPKA complex might depend on Pf14‑3‑3I
The combination of pull-down experiments with GST-
PfAKAL beads incubated with parasite protein extracts 
and nLC-MSMS analysis identified Pf14-3-3I [PlasmoDB: 
MAL8P1.69/PF3D7_0818200] [13], as a putative PfAKAL 
partner. We further investigated this interaction with 
GST-PfAKAL and (His)6-Pf14-3-3I recombinant pro-
teins. Purified GST-PfAKAL beads were incubated in 
purified (His)6-Pf14-3-3I solution, and binding analysed 
by anti-polyhistidine western blot. As expected, GST-
PfAKAL bound (His)6-Pf14-3-3I, while GST alone did 
not (Fig. 6a). To confirm this interaction, co-immunoflu-
orescence assays were performed on infected red blood 
cells with anti-PfAKAL and anti-Pf14-3-3I antibod-
ies. Pf14-3-3I is known to be present in both cytoplas-
mic and nuclear compartments of the parasite [13], but 
these locations seem more diffuse than that of PfAKAL 
throughout the parasite development. The distribution 
of the two proteins partially overlapped in the parasite 
cytoplasm and nucleus (Fig.  6b). Partial co-localiza-
tion was confirmed following deconvolution of the IFA 
Fig. 2 Pfakal expression levels in infected red blood cells. RT‑qPCR 
analyses were performed on synchronized P. falciparum asexual 
blood stages. The pfakal transcript abundance was calculated 
using the 2−ΔΔCt method where Ct is the threshold cycle, and 
��Ct=(Ct pfakal−Ct p90)stage x−(Ct pfakal−Ct p90)late trophozoite.  
Expression levels were normalized to pfakal gene transcription level 
in late trophozoites, the maximal expression observed throughout 
the erythrocyte cycle. The result for each sample was expressed by 
calculating the mean and standard deviations (bars on histograms) 
between the three experiments. A statistical analysis was performed 
with a Kruskal–Wallis test (p = 0.0077)
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images (Fig.  6c). When combined with pull-downs, the 
IFA images confirm the interaction between PfAKAL and 
Pf14-3-3I.
14-3-3 proteins are known to play scaffold functions 
in cells to stabilize multiple enzyme complexes includ-
ing PKA subunits [31], and to be phosphorylated by 
Hoechst
a
b
c
d
e
f
DICαPfAKAL
Hoechst + 
αPfAKAL
g
Fig. 3 PfAKAL subcellular localizations in asexual and sexual P. falciparum blood stages. Images with PfAKAL localization (green), Hoechst DNA stain‑
ing (blue), differential interference contrast (DIC) were taken on rings a trophozoites, b schizonts, c as well as on stage II, d stage III, e stage IV, f and 
stage V, g gametocytes, infected erythrocytes. “Bright orange” on DIC images indicates haemozoin crystals. The bars represent 2 μm
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cAMP-dependent kinases [32]. Therefore the interaction 
between Pf14-3-3I and PfPKA-R was investigated by pull-
down experiments involving recombinant proteins. Puri-
fied GST-PfAKAL, GST-PfPKA-R and GST (as control) 
beads were incubated in purified (His)6-Pf14-3-3I solu-
tion, and the complexes analysed by anti-polyhistidine 
western blot (Fig. 6d). Both PfAKAL (Fig. 6d, lane 4) and 
PfPKA-R (Fig.  6d, lane 5) interact with Pf14-3-3I sug-
gesting that Pf14-3-3I could mediate binding between 
the two proteins acting as a scaffold in the assembly of a 
PfPKA/PfAKAL complex. As PfPKA-R binds Pf14-3-3I it 
also suggests that Pf14-3-3I might be phosphorylated by 
DICHoechstαPfAKAL αPfΑΜΑ1 αPfΑΜΑ1+ αPfAKAL
a
b
Fig. 4 PfAKAL localization in P. falciparum merozoites by indirect immunofluorescence assays. Images with PfAKAL localization (green), PfAMA1 
localization (red), Hoechst DNA staining (blue) and differential interference contrast (DIC) and were taken. a P. falciparum 3D7 egressing merozoites, 
b P. falciparum 3D7 invading merozoite. The bars represent 2 μm
Fig. 5 Interaction between GST‑PfPKA‑R and (His)6‑PfAKAL protein. a Nitrocellulose membrane coloration and anti‑polyhistidine Western blot (b) 
after GST beads (2) and GST‑PfPKA‑R beads (8) were incubated in (His)6‑PfAKAL solution. Molecular marker (1), empty lane (3), (His)6‑PfAKAL (4), 
flowthrough after incubation of GST‑PfPKA‑R beads in (His)6‑PfAKAL solution (5), beads washes (6–7). The recombinant GST‑PfPKA‑R and (His)6‑
PfAKAL proteins molecular weight are 75 and 32 kDa respectively. c A peptide array was performed using peptides derived from the PfAKAL whole 
protein sequence. An anti‑polyhistidine western blot was realized to identify the peptides interacting with (His)6‑PfPKA‑R. d Gel filtration analysis of 
(His)6‑PfPKA‑R
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PfPKA-C, as phosphorylation of 14-3-3 by PKA has been 
reported to play a role in the regulation of the dimeriza-
tion of 14-3-3 [32]. An analytical gel filtration performed 
on (His)6-Pf14-3-3I samples demonstrated the dimeriza-
tion of Pf14-3-3I, as two pics were obtained on Superdex 
S200 10/300 Increase column (GE Healtcare), corre-
sponding to the size of a dimer (around 62  kDa) and a 
monomer of (His)6-Pf14-3-3I (around 31 kDa) (Fig. 6d). 
The nature of the proteins in the two eluted fractions was 
confirmed by 12.5 % SDS-PAGE analysis.
PKA phosphorylates PfPKA‑R and Pf14‑3‑3I
First, the PfAKAL protein sequence was analysed with 
an algorithm predicting PKA phosphorylation potential 
sites [33] and identified a single site with a very weak 
score. To investigate the potential phosphorylation of 
PfPKA-R and Pf14-3-3I, an in  vitro phosphorylation 
assay was performed with recombinant proteins (His)6-
Pf14-3-3I, (His)6-PfPKA-R and (His)6-PfAKAL. Plasmo-
dium falciparum (PfPKA-C) and bovine PKA catalytic 
subunits (PKA-C) share 48  % similarity in the overall 
primary sequence, but 80  % similarity in the activa-
tion segment that interacts with the substrate [34]. PKA 
phosphorylation sites also share a consensus sequence, 
R–R-X-S/T-Φ, where Φ represents a hydrophobic resi-
due. Therefore bovine PKA catalytic subunit could be 
used in our kinase assays, to assess the phosphoryla-
tion of the different proteins. The results showed the 
Fig. 6 (His)6‑Pf14‑3‑3I interaction with GST‑PfAKAL and GST‑PfPKA‑R. a Anti‑polyhistidine western blot analysis after incubation of GST‑PfAKAL 
beads in (His)6‑Pf14‑3‑3I solution. GST beads (1), molecular marker (2), flowthrough after incubation of GST‑PfAKAL beads in the (His)6‑Pf14‑3‑3I 
solution (3), glutathione agarose bead (4), and GST‑PfAKAL beads (5), incubated in (His)6‑Pf14‑3‑3I solution, (His)6‑Pf14‑3‑3I (6). b PfAKAL and Pf14‑
3‑3I localizations by immuno‑staining of 3D7 parasites infected erythrocytes smears with mouse anti‑PfAKAL (red) and rat anti‑Pf14‑3‑3I (green) 
antibodies. The merge shows colocalization of the two proteins (yellow). c Deconvolution microscopy analysis (Imaris software) on a trophozoite 
parasite showing PfAKAL (red) and Pf14‑3‑3I (green) localizations in the infected red blood cell, nucleus staining (blue). The pink and yellow colors 
represent the localizations where blue and red signals or green and red signals are merged respectively. The bars represent 2 μm, d Anti‑polyhistidine 
western blot analysis after incubation of GST‑PfPKA‑R beads in (His)6‑Pf14‑3‑3I solution. (His)6‑Pf14‑3‑3I (1); GST beads in (His)6‑Pf14‑3‑3I solution (2); 
molecular marker (3); GST‑PfAKAL beads in (His)6‑Pf14‑3‑3I solution (4); GST‑PfPKA‑R beads in (His)6‑Pf14‑3‑3I solution (5). e Gel filtration analysis of 
(His)6‑Pf14‑3‑3I showing two pics: pic 1 corresponds to a dimer of (His)6‑Pf14‑3‑3I and pic2 corresponding to a monomer of (His)6‑Pf14‑3‑3I
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phosphorylation of PfPKA-R and Pf14-3-3I by bovine 
PKA, and that these phosphorylations are inhibited by 
the potent PKA inhibitor H89 (Fig. 7). On the contrary, 
PfAKAL was not phosphorylated in vitro by bovine PKA 
(Fig.  7). The results confirmed the prediction of a weak 
probability for PfAKAL to be phosphorylated by PKA. 
Also, the PKA phosphorylation of PfPKA-R and Pf14-
3-3I were reinforced by P. falciparum schizont phospho-
proteome studies [29, 30].
As 14-3-3 proteins act as chaperones and bind actin 
to promote nuclear import or export [35, 36], Pf14-3-3I 
could play a role in the localization of PfAKAL, depend-
ing on the PKA-dependent phosphorylation state of Pf14-
3-3I. This hypothesis needs to be further investigated.
In silico structural analysis of PfAKAL protein reveals 
conservation of residues responsible for nucleotide 
binding
To determine the potential function of PfAKAL, the 
amino acid sequence was submitted to the I-TASSER 
server for protein structure prediction [15, 16]. The 
returned sequence alignments and structural analogues 
were human AKAP18, bacterial 2′–5′ RNA-ligase, cyclic 
nucleotide phosphodiesterase from Arabidopsis thaliana. 
The I-TASSER server also predicted five structural mod-
els for PfAKAL. The backbone chains of all five structural 
models share the same general shape, but differ in some 
secondary structures. In the highest scoring model, the 
N-terminus is folded in an alpha-helix, but its conforma-
tion and location are different from that observed in the 
other models, and a binding pocket is present. The back 
of this pocket is lined by two β-sheets, whereas there 
is only one β-sheet in the other models (Fig.  8a). This 
highest scoring model is displayed alongside the struc-
ture of human AKAP18 co-crystallized with cytidine-
5′-monophosphate (5′CMP) [7]. A superposition of 
PfAKAL structural model and human AKAP18 core 
domain structure confirmed that the two proteins share 
a similar shape (Fig. 8a). I-TASSER also predicted some 
binding sites [37] using human AKAP18 core domain 
and two phosphodiesterases from Arabidopsis thaliana 
and mouse. The highest scoring model, containing the 
predicted binding site from human AKAP18, highlights 
a possible interaction between PfAKAL and nucleotides 
such as AMP. The residues involved in AMP binding are 
conserved, but with some modifications in the orienta-
tion of the side chains (Fig. 8b).
A previous study also suggested that human AKAP18 
acts as an adenosine monophosphate (AMP) sensor in 
the cell, binding AMP within a groove, located between 
the two lobes of the protein, and specifically binding 
5′AMP and 5′CMP [7]. To investigate the nucleotide-
binding capability of PfAKAL with 5′AMP and 3′–5′ 
cAMP, pull-down experiments were performed with 
5′AMP immobilized on agarose beads in a solution of 
recombinant PfAKAL or in parasite protein extracts. 
Western blot analyses showed that recombinant (His)6-
PfAKAL interacts with 5′-AMP (Fig. 8c).
A mass spectrometry analysis of the native complexes 
from parasite protein extracts interacting with AMP-
beads also confirmed that native PfAKAL is a 5′-AMP 
binder. The binding of 5′-AMP did not interfere with 
the interaction between PfAKAL and Pf14-3-3I (Fig. 8d). 
AMP binding by PfAKAL suggests different functions 
PfAKALPfPKA-RPf14-3-3I
bPKAc + +- + +- + + + +-
H89 - +- - +- - + - +-
25
35
55
70
25
35
55
70
MW (kDa)
(His)6-PfPKA-R
(His)6-Pf14-3-3I
(His)6-PfAKAL
(His)6-PfPKA-R
(His)6-Pf14-3-3I
(His)6-PfAKAL
a
b
Fig. 7 Phosphorylation of (His)6‑PfPKA‑R, (His)6‑Pf14‑3‑3I or (His)6‑PfAKAL by bovine PKA catalytic subunit (bPKA). Radiolabel kinase activity assays 
were deployed to detect phosphorylation of the proteins. Assays without PKA or with H89, a potent PKA inhibitor were used as negative controls. 
Coomassie blue staining (b) of radiolabelled SDS‑gels (a) was used as a loading control
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for the protein. One possibility is that PfAKAL acts as 
a 5′-AMP effector within the parasite, where classically 
5′-AMP acts as an energy sensor triggering the AMP-
activated protein kinase (AMPK) signalling pathway. In 
eukaryotic cells, AMPK is ubiquitous and acts as a cel-
lular energy sensor, monitoring the AMP:ATP ratio. If 
an energy deficit is detected, AMPK activates or inhib-
its other pathways to restore energy homeostasis [38]. 
An AMPK has not been identified in P. falciparum 
until now, but BLAST analysis at PlasmoDB identified a 
putative actor in the AMPK signalling pathway, PfKIN 
(PlasmoDB identifier PF3D7_1454300), an as yet unchar-
acterized protein. Hanson and colleagues have shown 
that torins, a single structural class of mTOR inhibitors, 
are potent anti-malarials despite the absence of a recog-
nizable mTOR kinase in Plasmodium. As mTOR kinases 
are AMPK downstream targets [39], this could suggest 
the presence of an AMPK signalling pathway in malaria 
parasites [40]. Thus, a third hypothesis is that PfAKAL 
acts as an AMP-binder and a scaffolding protein in this 
putative pathway. Therefore, the interaction of recombi-
nant (His)6-PfAKAL with 3′–5′ cAMP was investigated 
(Fig. 8c). But the ability of PfAKAL to hydrolyse cAMP, 
because of its homology with bacterial phosphoester-
ases, still need to be established. Different AKAPs such 
as human AKAP18δ and mAKAP, have been shown to 
interact with PDE [41, 42], and PDE isoforms have been 
characterized in Plasmodium [11, 12] rendering possible 
an interaction between PfAKAL and PfPDEs.
Conclusions
This study presents the characterization of PfAKAL, a 
protein initially identified as a putative PfPKA anchor. 
Using molecular and biochemical approaches, we have 
demonstrated that PfAKAL is expressed in all intraeryth-
rocytic stages, including merozoites and gametocytes, 
but could not establish any direct protein–protein inter-
action with PfPKA-R. This suggests an alternative way of 
anchoring PfPKA within the parasite, and Pf14-3-3I is a 
PfPKA-R binding partner. The dimerization of Pf14-3-3I 
Fig. 8 PfAKAL homology‑based structural model and nucleotide binding studies, a Superposition of PfAKAL model with human AKAP18 central 
domain [PDB: 2vfl], represented with ribbon diagrams colored respectively in red and blue. b Superposition of PfAKAL model (red) with human 
AKAP18 that binds AMP [PDB: 2vfk] (blue). The residues involved in nucleotides binding are displayed as sticks, and AMP is colored in green. c Anti‑
polyhistidine western blot performed on precipitated protein complexes using cAMP‑ and AMP‑ agarose beads in (His)6‑PfAKAL solution. (His)6‑
PfAKAL (1); beads washes (2–4), cAMP beads in (His)6‑PfAKAL solution (5), AMP beads in (His)6‑PfAKAL solution (6). d Anti‑polyhistidine western 
blot analysis after incubation of GST‑PfAKAL beads in (His)6‑Pf14‑3‑3I solution in the presence (1) or absence (2) of 5 mM 3′–5′AMP; recombinants 
(His)6‑PfAKAL and (His)6‑Pf14‑3‑3I proteins molecular weight are 32 and 30 kDa respectively
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proteins could stabilize the N-terminus of PfPKA-R pro-
moting the dimerization of PfPKA-R monomers, so cre-
ating a docking domain for yet to be identified parasite 
AKAPs. As Pf14-3-3I is PKA phosphorylated by bovine 
PKA in  vitro, Pf14-3-3I dimerization and/or Pf14-3-3I 
interaction with PfPKA-R In  vivo may be regulated by 
phosphorylation. The results presented here also high-
light structural and biochemical similarities between 
PfAKAL and human AKAP18γ, including nucleotide 
binding such as AMP and cAMP. PfAKAL may play a 
role as an AMP sensor, or be involved in other pathways, 
such as AMPK or PDE pathways.
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